MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- LUPIN - SUN PHARMA
LUPIN vs SUN PHARMA - Comparison Results
LUPIN Change
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
SUN PHARMA 
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Current Valuations
| LUPIN | SUN PHARMA | LUPIN/ SUN PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 41.1 | 77.2 | 53.2% | View Chart |
| P/BV | x | 3.8 | 3.3 | 114.7% | View Chart |
| Dividend Yield | % | 0.6 | 0.6 | 88.8% |
Financials
 LUPIN  SUN PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| LUPIN Mar-20 |
SUN PHARMA Mar-20 |
LUPIN/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 882 | 484 | 182.2% | |
| Low | Rs | 505 | 315 | 160.2% | |
| Sales per share (Unadj.) | Rs | 339.4 | 136.9 | 248.0% | |
| Earnings per share (Unadj.) | Rs | -5.9 | 17.5 | -34.1% | |
| Cash flow per share (Unadj.) | Rs | 15.5 | 26.0 | 59.5% | |
| Dividends per share (Unadj.) | Rs | 6.00 | 4.00 | 150.0% | |
| Dividend yield (eoy) | % | 0.9 | 1.0 | 86.4% | |
| Book value per share (Unadj.) | Rs | 276.7 | 188.7 | 146.7% | |
| Shares outstanding (eoy) | m | 453.00 | 2,399.26 | 18.9% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.0 | 2.9 | 70.0% | |
| Avg P/E ratio | x | -116.6 | 22.9 | -509.3% | |
| P/CF ratio (eoy) | x | 44.8 | 15.4 | 291.7% | |
| Price / Book Value ratio | x | 2.5 | 2.1 | 118.3% | |
| Dividend payout | % | -100.9 | 22.9 | -440.2% | |
| Avg Mkt Cap | Rs m | 314,201 | 958,864 | 32.8% | |
| No. of employees | `000 | 18.3 | 17.8 | 103.1% | |
| Total wages/salary | Rs m | 29,868 | 63,624 | 46.9% | |
| Avg. sales/employee | Rs Th | 8,400.6 | 18,490.6 | 45.4% | |
| Avg. wages/employee | Rs Th | 1,632.0 | 3,582.6 | 45.6% | |
| Avg. net profit/employee | Rs Th | -147.2 | 2,357.6 | -6.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 153,748 | 328,375 | 46.8% | |
| Other income | Rs m | 4,838 | 6,360 | 76.1% | |
| Total revenues | Rs m | 158,585 | 334,735 | 47.4% | |
| Gross profit | Rs m | 24,849 | 69,898 | 35.6% | |
| Depreciation | Rs m | 9,702 | 20,528 | 47.3% | |
| Interest | Rs m | 3,630 | 3,027 | 119.9% | |
| Profit before tax | Rs m | 16,355 | 52,702 | 31.0% | |
| Minority Interest | Rs m | 4 | 0 | - | |
| Prior Period Items | Rs m | 39 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -7,521 | -2,606 | 288.5% | |
| Tax | Rs m | 11,571 | 8,228 | 140.6% | |
| Profit after tax | Rs m | -2,694 | 41,868 | -6.4% | |
| Gross profit margin | % | 16.2 | 21.3 | 75.9% | |
| Effective tax rate | % | 70.8 | 15.6 | 453.2% | |
| Net profit margin | % | -1.8 | 12.8 | -13.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 154,132 | 316,542 | 48.7% | |
| Current liabilities | Rs m | 92,252 | 157,064 | 58.7% | |
| Net working cap to sales | % | 40.2 | 48.6 | 82.9% | |
| Current ratio | x | 1.7 | 2.0 | 82.9% | |
| Inventory Days | Days | 82 | 88 | 93.8% | |
| Debtors Days | Days | 129 | 105 | 123.5% | |
| Net fixed assets | Rs m | 89,082 | 243,102 | 36.6% | |
| Share capital | Rs m | 906 | 2,399 | 37.8% | |
| "Free" reserves | Rs m | 124,461 | 450,245 | 27.6% | |
| Net worth | Rs m | 125,367 | 452,645 | 27.7% | |
| Long term debt | Rs m | 17,933 | 20,289 | 88.4% | |
| Total assets | Rs m | 249,839 | 682,525 | 36.6% | |
| Interest coverage | x | 5.5 | 18.4 | 29.9% | |
| Debt to equity ratio | x | 0.1 | 0 | 319.1% | |
| Sales to assets ratio | x | 0.6 | 0.5 | 127.9% | |
| Return on assets | % | 0.4 | 6.6 | 5.7% | |
| Return on equity | % | -2.1 | 9.2 | -23.2% | |
| Return on capital | % | 8.7 | 11.2 | 77.7% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 51,450 | 74,219 | 69.3% | |
| Fx outflow | Rs m | 19,470 | 27,964 | 69.6% | |
| Net fx | Rs m | 31,980 | 46,255 | 69.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 14,688 | 65,548 | 22.4% | |
| From Investments | Rs m | 11,070 | -25,888 | -42.8% | |
| From Financial Activity | Rs m | -8,906 | -57,151 | 15.6% | |
| Net Cashflow | Rs m | 16,853 | -13,857 | -121.6% | |
Share Holding
| Indian Promoters | % | 46.6 | 63.7 | 73.2% | |
| Foreign collaborators | % | 0.2 | 0.0 | - | |
| Indian inst/Mut Fund | % | 11.3 | 5.1 | 220.3% | |
| FIIs | % | 31.9 | 23.0 | 138.7% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.1 | 8.3 | 121.7% | |
| Shareholders | 98,259 | 133,026 | 73.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare LUPIN With: CIPLA PIRAMAL ENTERPRISES ALKEM LABORATORIES SHASUN PHARMA PFIZER
Compare LUPIN With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
6 Reasons Why Sensex Plunged 1,708 Points Today(Closing)
Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.
Related Views on News
SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)
Feb 1, 2021 | Updated on Feb 1, 2021For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)
Dec 11, 2020 | Updated on Dec 11, 2020Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
LUPIN 2019-20 Annual Report Analysis (Annual Result Update)
Dec 7, 2020 | Updated on Dec 7, 2020Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.
More Views on NewsMost Popular
A Critical Update on the Market(Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy(Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers(Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
MoreOUR TOP 5 IDEAS
- India's Revival: A Once-in-a-generation Wealth Making Opportunity
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
LUPIN SHARE PRICE
Apr 12, 2021 (Close)
TRACK LUPIN
- Track your investment in LUPIN with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON LUPIN
LUPIN 8-QTR ANALYSIS
COMPARE LUPIN WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.